PRQR
NASDAQProQR Therapeutics N.V.
News · 26 weeks53-37%
2026-03-012026-08-23
Mix2390d
- SEC Filings8(35%)
- Insider8(35%)
- Other4(17%)
- Offering2(9%)
- Analyst1(4%)
Latest news
25 items- ANALYSTBofA Securities initiated coverage on ProQR Therapeutics with a new price targetBofA Securities initiated coverage of ProQR Therapeutics with a rating of Buy and set a new price target of $8.00
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- PRProQR Announces Second Quarter 2026 Operating and Financial ResultsFirst clinical validation of Axiomer™ RNA editing established through NTCP modulation with positive AX-0810 clinical target engagement data; full Phase 1 dataset to be presented at a medical or scientific conference later this yearMultiple clinical milestones, including initial AX-0811 Phase 1 data expected by year-end 2026, followed in H1 2027 by: biliary atresia IIT initiation and initial data, initial AX-0422 (IDUA) patient data in MPS I Hurler syndrome, and advancement of AX-2911 (PNPLA3) to the clinic Strengthened balance sheet through $59.2 million financing during the quarter; ended Q2 2026 with € 117.1 million cash and cash equivalents, supporting runway through mid-2028 LEIDEN, Net
- INSIDERChief Executive Officer De Boer Daniel Anton bought $353,960 worth of Ordinary Shares (200,000 units at $1.77), increasing direct ownership by 67% to 500,000 units (SEC Form 4)4 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- SECSEC Form SCHEDULE 13G filed by ProQR Therapeutics N.V.SCHEDULE 13G - ProQR Therapeutics N.V. (0001612940) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ProQR Therapeutics N.V.SCHEDULE 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)
- INSIDERDirector Filius Bart bought $257,925 worth of Ordinary Shares (150,000 units at $1.72), increasing direct ownership by 100% to 300,000 units (SEC Form 4)4 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- SECSEC Form EFFECT filed by ProQR Therapeutics N.V.EFFECT - ProQR Therapeutics N.V. (0001612940) (Filer)
- SECSEC Form 424B5 filed by ProQR Therapeutics N.V.424B5 - ProQR Therapeutics N.V. (0001612940) (Filer)
- INSIDERChief Executive Officer De Boer Daniel Anton bought $261,000 worth of Ordinary Shares (150,000 units at $1.74), increasing direct ownership by 100% to 300,000 units (SEC Form 4)4 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- INSIDERChief Executive Officer De Boer Daniel Anton bought $238,500 worth of Ordinary Shares (150,000 units at $1.59) (SEC Form 4)4 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- SECSEC Form F-3 filed by ProQR Therapeutics N.V.F-3 - ProQR Therapeutics N.V. (0001612940) (Filer)
- INSIDERAmendment: SEC Form 4 filed by Director Hinsch Gylvin Lykke4/A - ProQR Therapeutics N.V. (0001612940) (Issuer)
- INSIDERDirector Filius Bart bought $231,000 worth of Ordinary Shares (150,000 units at $1.54) (SEC Form 4)4 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- SECSEC Form 424B5 filed by ProQR Therapeutics N.V.424B5 - ProQR Therapeutics N.V. (0001612940) (Filer)
- PRProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private PlacementLEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) ("ProQR"), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the pricing of an underwritten registered direct offering of 27,624,310 ordinary shares (the "Offering") at an offering price of $1.81 per share (the "Offering Price"), for total gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by ProQR. Concurrently with the Offering, ProQR has entered into a
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- PRProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing PlatformData from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the evaluable 3 mg/kg and 6 mg/kg cohortsAX-0810 demonstrated up to 8-fold change (6 mg/kg) in total bile acids in serum, exceeding the 2-fold threshold identified by the Company as a meaningful indicator of NTCP modulation, along with concordant readouts of bile acid profile and TUDCA markersFavorable safety and tolerability profile observed with AX-0810 to date, with no serious adverse events or pruritus reported; pharmacokinetic findings to date support sustained target engagement, including a half-life of eight weeksThe NTCP biomarker findings support ad
- INSIDERSEC Form 4 filed by Director Hinsch Gylvin Lykke4 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hinsch Gylvin Lykke3 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
PRQR FAQ
7 questionsWhat does ProQR Therapeutics N.V. do?
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial...Where does PRQR stock trade?
ProQR Therapeutics N.V. (PRQR) is listed on NASDAQ.What sector and industry is PRQR in?
ProQR Therapeutics N.V. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did ProQR Therapeutics N.V. go public?
ProQR Therapeutics N.V. (PRQR) completed its IPO in 2014.What are analysts saying about PRQR?
ProQR Therapeutics N.V. has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Buy with a $800.00 price target on 2026-08-20.What companies are similar to PRQR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PRQR side-by-side with any of them on Quantisnow.How can I track PRQR on Quantisnow?
Quantisnow aggregates ProQR Therapeutics N.V.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PRQR to receive live email and push alerts on every new disclosure.